SCHEMBL31000700

SCHEMBL31000700

O=C(N[C@H](C(=O)OCc1ccccc1)[C@H](O)c1ccccc1)OCC1c2ccccc2-c2ccccc21

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.48
▸ CASP3 P42574 4/20 0.46
▸ EPHX2 P34913 1/20 0.46
▸ HDAC1 Q13547 1/20 0.45
▸ HDAC2 Q92769 1/20 0.45
▸ MDM4 O15151 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ TNF P01375 1/20 0.43
▸ IDO1 P14902 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31000521 1.00 KMT2A (0.48) KMT2ACASP3EPHX2HDAC1HDAC2
SCHEMBL30638167 0.88 CTSL (0.53) KMT2ACASP3EPHX2HDAC1HDAC2
SCHEMBL13694941 0.88 CTSL (0.53) KMT2ACASP3EPHX2HDAC1HDAC2
SCHEMBL13695275 0.88 CTSL (0.53) KMT2ACASP3EPHX2HDAC1HDAC2
SCHEMBL29401180 0.88 CTSL (0.53) KMT2ACASP3EPHX2HDAC1HDAC2
SCHEMBL20401006 0.88 CTSL (0.53) KMT2ACASP3EPHX2HDAC1HDAC2
SCHEMBL15317927 0.87 CASP3 (0.51) KMT2ACASP3EPHX2MDM4TP53
SCHEMBL12067889 0.87 CASP3 (0.51) KMT2ACASP3EPHX2MDM4TP53
SCHEMBL17703894 0.87 CASP3 (0.50) KMT2ACASP3EPHX2MDM4TP53
SCHEMBL21243785 0.87 CASP3 (0.50) KMT2ACASP3EPHX2MDM4TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287138-A1 CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY MERCK SHARP & DOHME LLC 2024-08-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287138-A1 CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY TNF, TNFRSF1A, CD40 KMT2A 4601/4885CASP3 418/4885EPHX2 3577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback